Medtronic (NYSE:MDT) may have found itself in another bind with the U.S. Justice Dept., according to the medical device giant’s latest financial report.
In August 2011 the company received a DoJ request for more information about insulin pump replacements for Medicare beneficiaries, Medtronic reported. The device maker is "fully cooperating with this inquiry."
Medtronic did not respond to requests for comment.
It’s not the company’s 1st row with the DoJ. Earlier this year Medtronic closed the books on a years-long federal investigation into its controversial Infuse bone growth protein.
The office of the U.S. Attorney for the District of Massachusetts and the DoJ abandoned their civil and criminal probe into allegations of off-label marketing and concealed safety risks without finding evidence of wrongdoing, according to a press release.
The company is still battling patient injury lawsuit, including a complaint unsealed earlier this year that alleged that Medtronic installed a paid crony at the Journal of Spinal Disorders and Techniques in order to push positive – and possibly premature – data on its Infuse bone growth stimulant.
Late last year Medtronic agreed to pay $23.5 million to settle DoJ allegations that it offered illegal kickbacks to encourage doctors to use its implantable pacemakers and defibrillators. The Fridley, Minn.-based medtech titan admitted to no improper or unlawful action in settling the case.
